[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nanoplastics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nanoplastics":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100615361","microplastics-and-nanoplastics-in-patients-with-chronic-coronary-syndromes-100615361",false,"NCT07291609","Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes","CCS-Plastics","Inclusion Criteria:\n\nALL the following:\n\n1. Age \\> 18 years old;\n2. Suspected or known chronic coronary syndromes undergoing coronary CT angiography;\n3. Clinical indication to invasive coronary angiography;\n4. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Coronary CT angiography not available;\n2. Poor quality CCTA;\n3. Absence of native coronary stenosis \\>=50% at CCTA;\n4. Contraindications to invasive coronary angiography and percutaneous coronary intervention\n5. Life expectancy \\\u003C 1 year due to non-cardiac pathology","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","3 Years","OBSERVATIONAL","The CCS-plastics is an investigator-initiated, prospective, multicenter study of patients undergoing coronary CT angiography (CCTA) for suspected or known chronic coronary syndromes (CCS) referred to invasive coronary angiography for clinical indication. Patients identified as eligible for the protocol will be asked for written consent to participate in the study. The patients' dossiers will be uploaded and transmitted to the core laboratory for analysis. The routine management of the CCS patients will not be affected and all patients will be managed according to current standards. Invasive coronary angiography and coronary blood samples will be performed following the current standards, guidelines, and indications. During invasive coronary angiography, coronary blood samples will be collected per standard of care and sent to a centralized, specialized core laboratory for MNPs and biomarkers analysis. The central core lab for MNPs analyses will be the University of Campania Luigi Vanvitelli, Naples, Italy. The identification, quantification (concentration, mcg\u002Fml), and typing of plastic particles will be performed in each tube for each patient, using pyrolysis-gas chromatography-mass spectrometry (Py-GC\u002FMS) and laser direct infrared (LDIR) spectroscopy. The CCTA will be centrally analyzed by Centro Cardiologico Monzino to evaluate qualitative and quantitative plaque features. Patients will be followed clinically at 1 and 3 years per standard of care.",[25,26,27,28,29,30,31],"Chronic Coronary Syndrome","Microplastics","Nanoplastics","Coronary Artery Disease","Coronary Plaque","Computed Tomography","Pollution Exposure","RECRUITING","2026-06-06",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":36},"2025-01-01",{"date":40,"type":20},"2029-12-31",{"name":42,"class":43},"Azienda Ospedaliera \"Sant'Andrea\"","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100614499","microplastics-cirrhosis-and-portal-hypertension-100614499","NCT07280390","Microplastics, Cirrhosis and Portal Hypertension","The Impact of Microplastics and Nanoplastics on Liver Health and Cardiovascular Diseases in India","Inclusion Criteria:\n\n* Age range of 18-70 years\n* Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings.\n* Undergoing elective surgery or liver transplantation\n\nExclusion Criteria:\n\n* • Hepatocellular carcinoma\n\n  * Pregnancy or lactation\n  * Patients with HIV or retroviral therapy\n  * Prior liver interventions like locoregional therapy, presence of HCC, prior abdominal surgery","70 Years",{"count":54,"type":20},30,"Cirrhosis and portal hypertension are associated with an hyperdynamic circulation and hepatic inflammation, leading to complications like ascites, variceal bleeding, acute kidney injury, and higher infection risk. Microplastics (MPs) are a global plastic pollution issue, and studies have found plastic MPs or nanoparticles (NPs) contaminating human, animal and environmental ecosystems.It has been noted that the accumulation of MPs increases with a reduction in size of the plastic particle. MPs are categorized into primary particles such as manufactured plastics including pellets and cosmetic microbeads and secondary particles which originate from mechanical and ultraviolet disruption of large plastic particles. MPs can be ingested via food or beverages, especially plastic packaged comestibles or inhaled as environmental pollutants. Contamination of medications such as antibiotics, intravenous fluids, albumin and medical devices is another source of exposure to microplastics in patients with chronic liver disease (CLD)In particular exposure to endoscopic interventions, liver biopsy, and invasive procedures such as paracentesis and interventional radiology procedures can lead to plastic exposure and deposition of MPs in the liver and other tissues in patients with cirrhosis. It may be hypothesized that these may contribute to hepatic inflammation and progression of cirrhosis and portal hypertension.\n\nGlobally, there is new research on the influence of MPs on the environment, plant and animal ecosystems and human health.\n\nPolystyrene (PS) microspheres that concentrate in the liver, intestine and the kidneys of mammals disrupt lipid and energy metabolism, impair mucus secretion, and alter the microbiome. Therefore, studies are required to assess how and to what extent, MPs impact human health, and affect chronic diseases like cirrhosis and reduce longevity.\n\nThe study investigators will assess the presence of MPs in the liver, kidneys and intestine of patients with liver cirrhosis and compare it with those without underlying liver disease and determine the impact on portal hypertension and fibrosis, and cardiovascular and metabolic function.",[57,26,58,27,59,60],"Cirrhosis","Portal Hypertension Related to Cirrhosis","Pollution","Cirrhosis and Chronic Liver Disease",[26,27,62,57,63],"Plastic pollution","Portal hypertension","2026-05-13",{"date":66,"type":36},"2026-05-15",{"date":68,"type":36},"2026-05-01",{"date":70,"type":20},"2027-02-25",{"name":72,"class":43},"Post Graduate Institute of Medical Education and Research, Chandigarh",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100590254","microplastics-and-nanoplastics-mnps-in-patients-with-st-elevation-myocardial-infarction-stemi-100590254","NCT06965023","Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)","STEMI-Plastics","Inclusion Criteria:\n\nAll the following inclusion criteria should be fulfilled:\n\n1. Age \\> 18 years old;\n2. STEMI undergoing urgent invasive coronary angiography;\n3. Acute thrombotic coronary occlusion\u002Fsub-occlusion (TIMI 0\u002F1);\n4. Clinical indication to thromboaspiration;\n5. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to percutaneous coronary intervention;\n2. Hemodynamic instability or cardiogenic shock;\n3. End-stage chronic kidney disease;\n4. Life expectancy \\\u003C 1 year due to non-cardiac pathology.",{"count":82,"type":20},130,"Air pollution and microplastics pose major public health threats. Emerging data have shown that micro- and nanoplastics (MNPs) are ubiquitous environmental pollutants accumulating in human tissues, triggering inflammation and prothrombotic state. This study will investigate the presence and burden of MNPs within coronary thrombi\u002Fthromboaspirate of patients presenting with ST segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention and their association with cardiac damage, plaque vulnerability, microvascular obstruction, and cardiovascular events. Plaque vulnerability will be explored by optical coherence tomography, while microvascular obstruction will be assessed by bolus thermodilution and cardiac magnetic resonance. Participants will be followed up for 1-year to evaluate whether the presence and the burden of MNPs will be associated with a higher incidence of the cardiovascular events.",[85,26,27,31],"ST-elevation Myocardial Infarction (STEMI)",[87,26,27,88,89,90,91,59,92,93,94,95,96],"STEMI","Inflammation","OCT","Plaque composition","cardiac magnetic resonance","Exposome","Infarct Size","Coronary Microvascular Dysfunction","IMR","MRR","2025-05-01",{"date":99,"type":36},"2025-05-11",{"date":101,"type":36},"2025-04-22",{"date":103,"type":20},"2027-12-31",{"name":42,"class":43},10]